NCT01832415 - First Line Ovarian Cancer Treatment - Cohort Study | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2016

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG

Bevacizumab

Observation of bevacizumab administration in first line ovarian cancer treatment

Trial Locations (14)

Centre Hospitalier Lyon-sud, Pierre-Bénite

Centre Paul Papin, Angers

Clinique Tivoli, Bordeaux

Institut Bergonié, Bordeaux

Centre jean Perrin, Clermont-Ferrand

Centre Hospitalier Intercommunal, Fréjus

institut Paoli Calmette, Marseille

Clinique Valdegour, Nîmes

Centre Hospitalier Régional, Orléans

Arcagy-Gineco, Paris

Institut Jean Godinot, Reims

Clinique Armoricaine de Radiologie, Saint-Brieuc

ICO René Gauducheau, Saint-Herblain

Hôpital Civil, Strasbourg

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

lead

ARCAGY/ GINECO GROUP

OTHER